Update – Mycoplasma genitalium testing
- Posted on: Apr 5 2022
DPMG is pleased to announce a new test option for Mycoplasma genitalium
Mycoplasma genitalium (M. gen) is an emerging STI present in approximately 10.2% of women and 10.6% of men. Often misdiagnosed, M. gen shows similar symptoms to chlamydia, gonorrhea, and trichomoniasis making it difficult to clinically identify.
The CDC now recommends M. gen testing for all patients with recurring cervicitis and urethritis. The CDC recommends Nucleic Acid Amplification Test (NAAT) as a proven means of detection. The Aptima® Mycoplasma genitalium Assay from Hologic is a revolutionary assay specifically intended to detect M genitalium. According to the CDC, greater than 15% of male and female patients with nongonococcal STIs are at risk of acquiring MG, and its incidence is increasing. Undiagnosed and misdiagnosed cases of M genitalium infections may be one of the primary factors leading to untreated cases, suboptimal therapy, severe complications such as infertility, and the development of resistance to currently available antibiotics. The assay will curtail misdiagnoses and will assist with more rapid detection of the bacteria. As a result, more timely, accurate, and cost-effective therapy can be initiated.
For more information, including testing supplies and updated requisitions, please contact our Customer Service department or your Client Liaison.
Posted in: Updates